Results 261 to 270 of about 26,268,555 (308)

First-Line Treatment of Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor: A Case Report and Review of the Literature. [PDF]

Case Rep Oncol Med
Wen Q, Long M, Li F, Peng Y, Yi J, Wu Y, Wang D.   +6 more
europepmc   +1 more source

Clinical Experience with Emicizumab and Rituximab as First-Line Treatment in a Case Series of Acquired Hemophilia A. [PDF]

Hematol Rep
Ota H, Yasuda K, Toyota N, Masuoka K.
europepmc   +1 more source

First-Line treatment for transplant-ineligible newly diagnosed multiple myeloma: a Bayesian network meta-analysis of efficacy, safety, and high-risk subgroups. [PDF]

Front Immunol
Zhong D, Cheng H, Zeng L, Tian C, Liang C, Wei H, Xu M, Pang M, Ke Q, Tan X, Cen H, Liao C.   +11 more
europepmc   +1 more source

Economic value of finotonlimab plus bevacizumab versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma in China and the United States. [PDF]

Front Public Health
He Y, Jiang Q, Pan X, Deng L, Hu X, Yang Z, Lang W.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

First‐line pharmacological treatment of hypertension

Journal of Internal Medicine, 1992
Over the last two decades, the treatment of arterial hypertension has improved considerably. Several new well-tolerated antihypertensive drugs have be- come available which have enhanced the therapeutic possibilities available to the physician at the expense of other compounds such as the centrally acting sympatholytic agents.
Burnier M, Waeber B, Brunner HR
openaire   +3 more sources

Pathophysiology and First-Line Treatment of Osteoarthritis

Annals of Pharmacotherapy, 2002
OBJECTIVE: To review the pathophysiology of osteoarthritis (OA) and the various treatment modalities, focusing specifically on acetaminophen (APAP), nonsteroidal antiinflammatory drugs (NSAIDs), and cyclooxygenase-2 (COX-2) inhibitors as the primary treatment options.
Jesse H, Hogue, Tracey L, Mersfelder
openaire   +2 more sources

Management of failures of first line treatments

Digestive and Liver Disease, 2008
Up to 70% of the patients treated to prevent rebleeding will experience a bleeding episode within 2 years. The response should be adapted to the delay after the index bleed, the source and the severity of the haemorrhage, the underlying liver disease and the initial treatment to prevent rebleeding.
Bureau, Christophe, Vinel, Jean-Pierre
openaire   +3 more sources

First-line treatment of Hodgkin’s lymphoma

Current Hematologic Malignancy Reports, 2006
Substantial clinical progress over the last decades has made Hodgkin's lymphoma into one of the most curable human cancers in adults. About 80% of patients in all stages and of all histologic subtypes experience long-term disease-free survival. Modern treatment strategies aim to improve chemotherapy and radiotherapy, while minimizing therapy-related ...
Beate, Klimm, Andreas, Engert, Volker, Diehl   +2 more
openaire   +3 more sources

First-line treatment

2019
Treatment of GIST has dramatically advanced due to the advent of imatinib. Treatment results improved with treatment using imatinib in advanced and recurrent GIST, with a handful of patients surviving without progression for longer than 10 years. The most important predictive factor of the effect of imatinib is a c-kit gene mutation, with a gene ...
openaire   +2 more sources

Recognition and First-Line Treatment of Anaphylaxis

The American Journal of Medicine, 2014
The International Classification of Diseases (ICD)-9 included a code only for anaphylactic shock. The improved ICD-10 coding defines the different symptoms and types of anaphylaxis and includes coding for anaphylaxis without shock. This new coding is consistent with the efforts of the National Institute of Allergy and Infectious Diseases (NIAID) and ...
openaire   +2 more sources